{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:22:21Z","timestamp":1774437741609,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0137660","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T17:54:21Z","timestamp":1441994061000},"page":"e0137660","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy"],"prefix":"10.1371","volume":"10","author":[{"given":"Kuan-Yin","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sih-Han","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristine","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Song","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hua","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mon-Ro","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Po","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3109\/0886022X.2014.900424","article-title":"The association between renal stone disease and cholesterol gallstones: the easy to believe and not hard to retrieve theory of the metabolic syndrome","volume":"36","author":"MH Ahmed","year":"2014","journal-title":"Ren Fail"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5009\/gnl.2012.6.2.172","article-title":"Epidemiology of gallbladder disease: cholelithiasis and cancer","volume":"6","author":"LM Stinton","year":"2012","journal-title":"Gut Liver"},{"key":"ref3","first-page":"e86","article-title":"Kidney stones: a global picture of prevalence, incidence, and associated risk factors","volume":"12","author":"V Romero","year":"2010","journal-title":"Rev Urol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/jac\/dkt514","article-title":"Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection","volume":"69","author":"T Nishijima","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/end.2011.0639","article-title":"Prevalence of nephrolithiasis in human immunodeficiency virus infected patients on the highly active antiretroviral therapy","volume":"26","author":"OA Raheem","year":"2012","journal-title":"J Endourol"},{"key":"ref6","article-title":"Crixivan (Indinavir Sulfate): Full Prescription Information (Package Insert)","year":"2013"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e77268","DOI":"10.1371\/journal.pone.0077268","article-title":"Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients","volume":"8","author":"T Nishijima","year":"2013","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/cid\/cis621","article-title":"High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy","volume":"55","author":"Y Hamada","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e69845","DOI":"10.1371\/journal.pone.0069845","article-title":"Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?","volume":"8","author":"Y Hamada","year":"2013","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/jac\/dkl112","article-title":"The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity","volume":"57","author":"MA Boyd","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/ftd.0b013e318030839e","article-title":"Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults","volume":"29","author":"F Collin","year":"2007","journal-title":"Ther Drug Monit"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/11631070-000000000-00000","article-title":"Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use","volume":"72","author":"E Foca","year":"2012","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/jac\/dku304","article-title":"Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3&apos; untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study","volume":"69","author":"T Nishijima","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/653427","article-title":"Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency","volume":"51","author":"WB Park","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref15","unstructured":"Centers for Disease Control, R.O.C. (Taiwan). Guidelines for diagnosis and treatment of HIV\/AIDS. 2013. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cdc.gov.tw\/uploads\/files\/201310\/1e64c227-32fc-49ab-8bfc-9484ec50c4f3.pdf\" xlink:type=\"simple\">http:\/\/www.cdc.gov.tw\/uploads\/files\/201310\/1e64c227-32fc-49ab-8bfc-9484ec50c4f3.pdf<\/ext-link>. Accessed 9 March 2015."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e88497","DOI":"10.1371\/journal.pone.0088497","article-title":"Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy","volume":"9","author":"KY Lee","year":"2014","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1128\/AAC.00098-06","article-title":"Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection","volume":"50","author":"S Colombo","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchromb.2006.03.014","article-title":"Simple and rapid liquid chromatography method for determination of efavirenz in plasma","volume":"835","author":"G Ramachandran","year":"2006","journal-title":"J Chromatogr B"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","article-title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects","volume":"69","author":"I Cascorbi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(95)90702-5","article-title":"Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert&apos;s syndrome","volume":"345","author":"S Aono","year":"1995","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bpg.2006.05.004","article-title":"Gallstone disease: Epidemiology of gallbladder stone disease","volume":"20","author":"EA Shaffer","year":"2006","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-230X-14-83","article-title":"Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan","volume":"14","author":"JY Chen","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2012.12.105","article-title":"Epidemiology of upper urinary tract stone disease in a Taiwanese population: a nationwide, population based study","volume":"189","author":"WY Huang","year":"2013","journal-title":"J Urol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.urology.2007.09.034","article-title":"Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005","volume":"71","author":"T Yasui","year":"2008","journal-title":"Urology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1056\/NEJMoa1404446","article-title":"Ultrasonography versus computed tomography for suspected nephrolithiasis","volume":"371","author":"R Smith-Bindman","year":"2014","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2893.2009.01141.x","article-title":"Hepatitis C virus infection is a risk factor for gallstone disease: a prospective hospital-based study of patients with chronic viral C hepatitis","volume":"16","author":"M Acalovschi","year":"2009","journal-title":"J Viral Hepat"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(06)68071-9","article-title":"Kidney stones: pathophysiology and medical management","volume":"367","author":"OW Moe","year":"2006","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/135965350000500105","article-title":"Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection","volume":"5","author":"B Malavaud","year":"2000","journal-title":"Antivir Ther"},{"key":"ref29","article-title":"Reyataz (Atazanavir Sulfate): Full Prescription Information (Package Insert)","year":"2012"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/QAD.0b013e32813aee35","article-title":"Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration&apos;s Adverse Event Reporting System","volume":"21","author":"KM Chan-Tack","year":"2007","journal-title":"AIDS"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/cid\/cis620","article-title":"Complicated atazanavir-associated cholelithiasis: a report of 14 cases","volume":"55","author":"S Rakotondravelo","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e112836","DOI":"10.1371\/journal.pone.0112836","article-title":"Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study","volume":"9","author":"M Lafaurie","year":"2014","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"19560","DOI":"10.7448\/IAS.17.4.19560","article-title":"Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens","volume":"17","author":"E Nkhoma","year":"2014","journal-title":"Journal of the International AIDS Society"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"D Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1001\/archinte.1994.00420220069008","article-title":"Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease","volume":"154","author":"JA Shea","year":"1994","journal-title":"Arch Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0137660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T18:07:47Z","timestamp":1653156467000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0137660"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,11]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0137660","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,11]]}}}